(1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-amine
CAS3039517-14-8
(1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-amine (CAS 3039517-14-8) is supplied by ChemSigma for research and manufacturing, with specification, analytical methods and batch documentation available on request.
- CAS No.
- 3039517-14-8
Chemical Specifications
Identifiers
| CAS number | 3039517-14-8 |
|---|---|
| Product name | (1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-amine |
| Chinese name | (1R)-1-[2-溴-6-(二氟甲氧基)苯基]-7-氯-2,3-二氢-1H-吡咯并[1,2-a]苯并咪唑-3-胺 |
Packaging, Storage & Transport
| Available pack sizes | 5kg, 1kg, 500g, 100g, 50g, 10g |
|---|
Read the current safety data sheet before handling. Packaging can be adapted to the order quantity and destination.
Frequently Asked Questions
What is the CAS number of (1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-amine?
The CAS Registry Number of (1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-amine is 3039517-14-8.
How can I request a quotation for (1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-amine?
Send an inquiry for (1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-amine (CAS 3039517-14-8) with the required quantity, target specification, destination country and any documentation requirements. ChemSigma will confirm availability, packaging, lead time and price.
Request a Quote for (1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-amine
Tell us the required quantity, target specification, destination country and any documentation requirements. We will confirm availability, packaging, lead time and price.
Need custom synthesis or scale-up? Our group company CKS Technology offers custom synthesis, process development and scale-up.